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In the brain, glycogen is a source of glucose not only in emergency situations but also during normal
brain activity. Altered brain glycogen metabolism is associated with energetic dysregulation in patho-
logical conditions, such as diabetes or epilepsy. Both in humans and animals, brain glycogen levels have
been assessed non-invasively by Carbon-13 Magnetic Resonance Spectroscopy (13C-MRS) in vivo. With
this approach, glycogen synthesis and degradation may be followed in real time, thereby providing
valuable insights into brain glycogen dynamics. However, compared to the liver and muscle, where
glycogen is abundant, the sensitivity for detection of brain glycogen by 13C-MRS is inherently low. In this
review we focus on strategies used to optimize the sensitivity for 13C-MRS detection of glycogen. Namely,
we explore several technical perspectives, such as magnetic ﬁeld strength, ﬁeld homogeneity, coil design,
decoupling, and localization methods. Furthermore, we also address basic principles underlying the use
of 13C-labeled precursors to enhance the detectable glycogen signal, emphasizing speciﬁc experimental
aspects relevant for obtaining kinetic information on brain glycogen.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Glucose is a universal energy fuel whose oxidation supports
cellular work. The brain, in particular, is highly dependent on
glucose oxidation and is, therefore, responsible for a substantial
fraction of basal blood glucose uptake [1]. Mammalian cells obtain
glucose not only from the blood but also from intracellular stores
located in the cytosol. In these stores glucose exists as a polymer:
glycogen. Polymerization allows for the presence of large amountsesonance spectroscopy; 13C-
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1 627 Ecole Polytechniqueof glucose inside the cell without consequences to osmolality or
concentration-gradient based exchanges with the blood, where
physiological glucose concentration is ~5 mM. Glycogen is found in
several organs, including the brain. In this review we brieﬂy over-
view the biochemistry, structure and function of glycogen, as
elucidated mainly by studies performed in the liver and skeletal
muscle, the two largest stores of glycogen in the body. Then, we
focus on the role of glycogen in the brain and give some examples of
altered glycogen metabolism in human diseases.
Magnetic resonance (MR) methods in vivo, notably MR spec-
troscopy (MRS), are a unique and versatile tool to assess metabolite
concentrations in a given organ, and to follow their dynamic
changes non-invasively and in real time. Carbon-13 MRS (13C-MRS)
is currently the state-of-the-art technique to study glycogen
metabolism in vivo in humans and rodents. Such studies have
explored glycogen dynamics under different physiological condi-
tions and have been expertly discussed in a recent review by
Khowaja et al. [2]. Therefore, in the second half of this review, we
rather focus on relevant technical and experimental aspects that
should be considered for optimization of glycogen detection and
data interpretation.
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Mammalian glycogen is composed of several chains of 11e16
glucose molecules [3] linked by linear a-(1,4) glucosidic bonds or
branching a-(1,6) glucosidic bonds [4]. The succession of branches
forms a bush-shaped spherical particle (b-particle) organized in
tiers, with an average diameter of ~20 nm [5]. This structure is
optimized to be stored in the smallest possible volume while
keeping the glucosyl units easily accessible to enzymes involved in
glycogen metabolism [6]. The glycogen molecule is built from a
protein primer, glycogenin [7], and it is now clear that glycogen is
directly associated to several other proteins, including those
involved in its own metabolism (e.g. glycogen synthase, glycogen
phosphorylase, or glycogen branching and debranching enzymes)
and other metabolically relevant ones [8]. Because these glycogen
granules are actually a collective structure of polysaccharide chains
with their own metabolic machinery they have been referred to as
an organelle-type particle, the so-called glycosome [9].
Glycogen granules assume different structural organizations
depending on the tissue of origin and in accordance with the
function they serve. For instance, in skeletal muscle, glycogen exists
mostly as ~20 nm b-particles, also called proglycogen, whose size
may reach up to ~40 nm (macroglycogen) with the addition of more
glucosyl units [8]. The abundance of smaller proglycogen particles,
with a proportionally higher content of metabolically active en-
zymes, seems to serve the purpose of ensuring a readily expendable
glucose source for muscular work [8]. On the other hand, in the
liver and cardiac muscle, b-particles are often clustered into larger
aggregates of ~150 nm: a-particles [10]. Such aggregation occurs
presumably via covalent or strong non-covalent bonds [11].
Differently from skeletal muscle glycogen, these larger particles
with a proportionally lower protein content [9] would be in line
with a slower mobilization of glucosyl units for hepatic glucose
output during progressive fasting. Interestingly, the formation of a-
particles in the liver appears to occur during net glycogen degra-
dation, providing a mechanism to control glucose release [12,13].3. Brain glycogen
Brain metabolism mainly relies on glucose oxidation. Glycogen
represents the largest store of glucose equivalents in the brain [14]
with its concentrations ranging from 3 mmol/g1 to 10 mmol/g in the
rodent [15e20] and human brain [21]. Glycogen concentration
exhibits regional differences [16,17,22e25], e.g. reaching over
20 mmol/g in corpus callosum of rats [17].
Structurally, glycogen exists both as b- and a-particles in as-
trocytes [26]. Despite expressing all the necessary enzymes for
glycogen synthesis, this pathway remains mostly inactive in neu-
rons [27]. At the cellular level, glycogen biogenesis from glucose
requires the sequential activities of hexokinase (glucose /
glucose-6-phosphate), phosphoglucomutase (glucose-6-phosphate
/ glucose-1-phosphate), uridine diphosphate (UDP)-glucose
pyrophosphorylase (glucose-1-phosphate / UDP-glucose) and
glycogen synthase, which adds glucosyl residues from UDP-glucose
to the glycogen molecule via a-(1,4) bonds. Branching of the
glycogen molecule is afforded by the branching enzyme that cata-
lyzes the formation of a-(1,6) glucosidic bonds. By glycogen phos-
phorylase activity, glucosyl units are released from glycogen in the
form of glucose-1-phosphate, and this intermediate is further
converted to glucose-6-phosphate by phosphoglucomutase1 mmol/g is an abbreviation of mmol per gram of wet weight of tissue. The use of
mmol/g for living tissue assumes an organ density of ~1000 g/L, which makes mmol/
g equivalent to mmol/kg and mM.activity.
While it is generally accepted that brain glycogen is not a ﬁrst-
line oxidative fuel, it becomes metabolically relevant under con-
ditions where energy demand can no longer be met by blood-
derived glucose. Indeed, a large body of pre-clinical studies dem-
onstrates such glycogen-dependent neuronal activity in stress sit-
uations. Illustrative examples comprise the reduction of brain
glycogen levels during intense exercise [28], hypoglycemia [29,30],
global ischemia [22] or sleep deprivation [17]. Importantly, it is now
recognized that glycogen is key for normal brain function beyond
representing an emergency energy reserve [16]. For example,
glycogen has been proposed as an expeditious energy source sup-
porting glutamatergic neurotransmission [31]. In agreement, brain
glycogen was shown to be of particular relevance during brain
activation [32,33] and learning [34e36], when increasing energy
demands need to be rapidly met. Conversely, cerebral glycogen
stores have to be adequately replenished when neuronal activity is
low and a glucose surplus is available, what has been shown to
occur during anesthesia, sleeping or hibernation [16].
Therefore, glycogen metabolism in the brain is a highly dynamic
process that adapts to activation and resting periods in a comple-
mentary fashion. For instance, brain glycogen levels may double
relative to the basal when recovering from severe hypoglycemia
[29,37], intensive exercise [28], and sleep deprivation [17,38]. This
phenomenon closely resembles glycogen supercompensation as
described in the skeletal muscle after exercise [39], suggesting a
similar organization of glycogen and associated enzymatic ma-
chinery in both tissues. Indeed, the muscle isoforms of glycogen
synthase and phosphorylase (which are mostly found but not
restricted to the skeletal muscle) are also expressed in the brain
[40].
Themetabolic pathways downstream glycogen degradation that
are involved in supporting brain energy metabolism remain to be
fully characterized. Although efforts have beenmade to understand
the precise fate of mobilized glycogen carbons, this topic is still
subject of debate. Glycogen-derived glucose-6-phosphate may
follow one of two pathways: (i) the pentose phosphates pathway or
(ii) glycolysis yielding pyruvate that may be further converted to
lactate. In particular, the efﬂux of glycogen-derived lactate from
astrocytes has been associated with brain activation, notably in the
scope of memory formation [32,36]. It has also been proposed that
lactate may serve as a relevant energy fuel for neurons when en-
ergy demands increase [36,41]. However, this so-called lactate
shuttle hypothesis [42] would only explain a small fraction of
neuronal energy metabolism in the activated brain, with most of
the glycogen-derived lactate being released from the brain [32].
4. Brain glycogen and energetic dysfunction in disease
Perturbations of glycogen dynamics may account for brain
metabolic dysregulation, compromising normal brain function.
Studies in genetically modiﬁed mice clearly highlight essential
roles of glycogen in the brain: for example, mice lacking glycogen
synthase in the brain do not have cerebral glycogen and show
hampered performance in memory tasks [34] as well as a higher
susceptibility to epilepsy [43]. On the other hand, accumulation of
glycogen in neurons may contribute to neurological decline with
aging, reproducing features of neurodegenerative diseases [44,45].
In addition, defects in glycogen branching leading to the formation
of aggregates inside neurons underlie the most severe form of
adolescence-onset epilepsy, Lafora disease [45]. Less prominent
alterations of brain glycogen metabolism also contribute to brain
energy dysfunction associated with other human diseases, such as
epilepsy [46] or diabetes [47], as further discussed in the following
paragraphs.
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be strongly reduced within a few minutes of continuous seizure
activity [48,49]. In a model of chemically-induced seizures, brain
glycogen content was shown to increase several hours after seizure
activity, presumably playing a role in the resistance to seizures [50].
In humans, glycogen levels in hippocampal biopsies from epileptic
patients were found to be higher than those in white and grey
matter biopsies [51]. Because this feature was reproduced in
healthy pigs, it might reﬂect differences in regional glycogen dis-
tribution, both in pigs and humans [51]. Also in rats, the hippo-
campus is amongst the brain regions displaying higher glycogen
content [16,22,24]. However, brain glycogen accumulation speciﬁc
to epilepsy would be in agreement with supercompensation
following seizure-induced glycogen depletion. In addition, elevated
glycogen levels could also energetically sustain neuronal activity
during seizures [51]. Taken together, these studies implicate cere-
bral glycogen in the energetics of seizure activity.
Altered brain glycogen metabolism has also been observed in
diabetes. An in vitro study found the activity of hexokinase
(engaging glucose in glycolysis) reduced whereas those of glycogen
phosphorylase and synthase increased in cortical slices of diabetic
rats, suggesting glycogen to be a more important fuel than glucose
for oxidation in this case [52]. Increased activity of glycogen syn-
thase has also been found in the cortex of type 1 diabetic rats,
however without any concentration alterations [53]. These ﬁndings
indicate that perturbed glycogen metabolism is one key feature of
the diabetic brain, not necessarily accompanied by modiﬁcations of
net glycogen content. Moreover, given the regional differences in
brain glycogen content [16,17,22e25], heterogeneity of glycogen
metabolism in diabetic brain may be anticipated. For instance,
glycogen pools across the brain have been shown to be differently
affected by diabetes, e.g. reduced glycogen levels were found in the
cerebellum of type 2 obese diabetic rats [54], and increased
glycogen content was reported in the retina of type 1 diabetic rats
[53]. Altered brain glycogen metabolism in diabetes may play an
important role in hypoglycemia unawareness, a situationwhere the
blood glucose threshold to elicit a counter-regulatory response is
reduced [29,47,55e58]. Glycogen supercompensation could
contribute to the development of hypoglycemia unawareness in
diabetic patients suffering from recurrent hypoglycemia episodes.
However, unlike ﬁndings for acute hypoglycemia [29], chronic hy-
poglycemia induced in rats was not accompanied by brain glycogen
supercompensation as assessed in vivo by 13C-MRS, but rather by
higher brain glucose levels [57]. In line with those studies, a13C-
MRS study in humans also failed to demonstrate glycogen super-
compensation in diabetic patients with hypoglycemia unawareness
[59], unlike ﬁndings in healthy volunteers after a single hypogly-
cemic episode [37]. By assessing both brain glucose and glycogen
contents in rats recovering from acute or chronic hypoglycemia,
Herzog et al. [30] found the restoration of brain glucose levels to be
faster in the latter case, and to happen together with a more rapid
increase in brain glycogen stores, without supercompensation. The
authors also conﬁrmed that epinephrine response was blunted in
chronic-relative to acute hypoglycemia. Therefore, glycogen
supercompensation is not a major contributor to defective counter-
regulation in hypoglycemia unawareness, but the latter phenom-
enon is certainly linked to alterations in the metabolic pathways
accounting for glucose-glycogen interconversion in the brain.
5. Non-invasive MR detection of cerebral glycogen
Proton-MRS (1H-MRS) is the most direct method to assess me-
tabolites in vivo, since the natural abundance of the 1H isotope is
~100%. The complete visibility of glycogen by 1H-MRS has been
demonstrated in solution [60,61]. In the body, the liver is the organwith the highest glycogen content: ~300 mmol/g, as measured in
tissue biopsies from human subjects [62]. Glycogen has been
observed by 1H-MRS in vivo in the liver of humans [63] and mice
[64], but this technique fails to account for the totality of hepatic
glycogen stores. More precisely, a concentration of ~40 mmol/g was
estimated for the human liver [63]. The incomplete visibility of
glycogen by 1H-MRS in vivo has been attributed to its short spin-
spin relaxation time (T2) [60,65]. This feature hampers glycogen
detection by any localized 1H-MRS sequences that make use of echo
formation between excitation and acquisition. During the period of
the echo formation, an important fraction of glycogen's magneti-
zation is lost due to spin-spin relaxation phenomena, hence
becoming unavailable for detection in the course of acquisition. An
additional difﬁculty for 1H-MRS detection of glycogen is that the
best resolved 1H resonance of that molecule has a chemical shift of
5.4 ppm, very close to that of water at 4.7 ppm, and is likely affected
by the high number of saturation pulses used for suppressing both
water and unwanted signals from outside of volume of interest
(VOI) in all localized 1H-MRS methods [66,67]. Therefore, quanti-
tative 1H-MRS detection of glycogen remains challenging and even
more so in organs with low glycogen content, such as brain.
An alternative approach to 1H-MRSwould be chemical exchange
saturation transfer MR imaging (CEST MRI), which is sensitive to
the interaction of water protons with exchangeable protons in
metabolites, such as hydroxyl groups. This technique can thus
detect low-concentration metabolites through the saturation of
rapidly exchanging protons on these metabolites [68]. CEST MRI
has been explored for assessing glycogen content in perfused liver
[69] and to some extent in human skeletal muscle [70]. However,
the feasibility of these so-called glycoCEST assessments remains to
be demonstrated for cerebral glycogen in vivo.
Differently from 1H-MRS, the complete visibility of glycogen by
13C-MRS has been demonstrated in vivo in the liver [71], skeletal
muscle [72] and also brain [58]. In fact, because 13C-MRS sequences
applied in the aforementioned studies are essentially pulse-
acquire, this technique is suited for compounds with an ultra-
short T2, such as glycogen. Therefore, 13C-MRS is the state-of-the-
art technique to assess cerebral glycogen in vivo and shares very
similar technical challenges with 13C-MRS detection of other car-
bohydrates, previously reviewed by, e.g., Gruetter et al. 2003 and de
Graaf et al. 2011 [73,74], and in this issue as well. Nonetheless,
speciﬁc properties of brain glycogen make it worth highlighting
how its detection by 13C-MRS in vivo beneﬁts from a careful opti-
mization of technical settings and experimental parameters. First
and foremost, the amount of naturally occurring 13C atoms in brain
glycogen is very low. The 13C isotope of carbon displays a natural
abundance of 1.11% and, since glycogen was found in the range of
3e10 mmol/g in the human and rodent brain [15e21], this yields
that only 0.03e0.1 mmol/g can be detected by 13C-MRS in vivo. In
addition, the unique physical properties of glycogen: ultra-short T2
and comparable spin-lattice relaxation time (T1, see Table 1), have
to be taken into consideration when selecting and developing the
technical tools for its 13C-MRS detection. Specially, echo-based
localization methods are not practicable for measuring cerebral
glycogen in vivo.
In the following sections, we will focus on strategies to improve
the sensitivity of 13C-MRS detection of glycogen C1. Firstly, we
explore the beneﬁts arising from technical development of both
hardware and MR sequence design. And lastly, we discuss the
experimental approach of brain glycogen studies in vivo that
currently relies on the administration of exogenous 13C-enriched
glucose precursors to increase the detected 13C-1 signal of
glycogen.
Table 1
T1 and T2/T2*/T2app for13C1 glycogen.
B0 (T) T1 (ms) T2/T2*/T2app (ms) Temperature (C) References
2.1 220 ± 10 11e31.1 27 Sillerud LO and Shulman RG 1983 [109]
65 ± 5 6.7 ± 1 22 Zang L et al., 1990 [110]
4.7 162 ± 6 7.3a-15.1b 37 Overloop K et al., 1996 [111]
158 ± 15* 5 ± 2* 37 Zang L et al., 1990 [110]
142 ± 10 9.4 ± 1 22 Zang L et al., 1990 [110]
5*,d 37 Gruetter R et al., 1994 [71]
8.4 304 ± 5 7.8a-13.3b 37 Overloop K et al., 1996 [111]
310 ± 10 13 ± 2 37 Zang L et al., 1990 [110]
300 ± 10 9.5 ± 1 22 Zang L et al., 1990 [110]
9.4 332 ± 15* 6.6 ± 1.1*,d 37 Van Heeswijk RB et al., 2012 [78]
340 ± 10c N/D 37 Choi IY et al., 2000 [80]
330 ± 30* N/D 37 Choi IY et al., 2000 [80]
14.1 521 ± 34* 5.9 ± 1.0*,d 37 Van Heeswijk RB et al., 2012 [78]
a,b 11.1 mM glycogen 13C1.
“*”measurements in vivo.
N/D not detected.
a 13C1-a and.
b 13C1-b
c 400 mM natural abundance oyster glycogen (4.4 mM glycogen13C1).
d Estimated from the spectral linewidth.
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6.1. Effect of higher magnetic ﬁelds (B0)
Sensitivity is known to be enhanced with the increase of mag-
netic ﬁeld strength (B0), i.e. signal-to-noise ratio (SNR) f B0b
[13,21,37,59,75e77]. In theory, when the sensitivity exclusively
depends on B0, the signal increases with B20 (b ¼ 2). However in
practice, b falls in the range of 1e1.75 due to noise arising from
electric hardware components, the sample itself, or other random
sources. Consequently, with b~1, the sensitivity increases linearly
with B0. Thus, at high ﬁelds, the acquisition time required to ach-
ieve SNR levels similar to those obtained at lower ﬁelds can be
shortened, as shown for 13C-MRS detection of glycogen C1 at 14.1 T
vs. 9.4 T [78].6.2. Radio-frequency (RF) coil design
Design of the RF coil (see reviews fromMagill and Gruetter [79],
and Ipek in the current issue) can be tailored to improve detection
of glycogen 13C-1 by providing high sensitivity at the 13C frequency
without exceeding the speciﬁc absorption rates (SAR) limits at the
1H frequency when using 1H decoupling. This feature is critical
when developing a coil for 13C-MRS since decoupling is commonly
used to improve 13C signal detection (see discussion below) and
SAR limits are highly restricted for human applications, even more
so at ultra-high magnetic ﬁeld.
In general terms, a typical 13C-MRS experiment requires a
double tuned 13Ce1H transceiver coil, in which the 13C-coil detects
13C signals and the 1H-coil is used for: (i) anatomical imaging for
precise placement of VOI; (ii) adjusting ﬁeld inhomogeneity; (iii)
decoupling JCH-coupling. For instance, 13C-linear coils (i.e. single 13C
loop) in combination with 1H-quadrature coils (i.e. two physically-
decoupled overlapped 1H loops) have been widely used both in
animal [18,29,57,58,78,80,81] and human studies [21,76,77,82].
Relative to the linear coil design, an overlapped quadrature coil
enhances sensitivity by a factor of √2 [79,83], and 13C-quadrature
coils have been designed in combination with either a 1H-volume
coil [84] or a 1H-quadrature coil [85]. Indeed, an SNR enhancement
of nearly √2 has been achieved to detect glycogen 13C-1 in vivo at
7 T with the latter design when comparing to the linear-13C/
quadrature-1H coil [85].
Besides coil design, it is also crucial to eliminate any unwantednoise introduced in the paths of RF chains, which can be afforded by
inserting bandpass (1H pass, 13C stop)/lowpass (13C pass, 1H stop)
ﬁlters in between the corresponding paths of RF chains [73,74,79].6.3. Decoupling
Most carbons of biomolecules, including glycogen, are directly
bonded to protons and experience JCH-coupling, which splits 13C
signals into multiplets. The 1H-coil can offer efﬁcient decoupling,
collapsing the multiplets into singlets, simplifying the 13C spectra
and effectively increasing the sensitivity [86].
Decoupling relies on the use of RF pulses that, like excitation
pulses delivered by the 13C-coil, also contribute to the SAR. Even
though the decoupling RF pulses have been developed towards
increasing decoupling bandwidth without exceeding the SAR for
human applications, most 13C-MRS applications on brain glycogen
have relied on a low-power broadband WALTZ-16 decoupling
scheme [86], which can be shortened [76,80,85,87] in adaptation to
the very short T2 of glycogen C-1 (Table 1). Nevertheless, in most
brain glycogen measurements by 13C-MRS, there is also an interest
in assessing brain glucose signals and, for this, longer duration RF
decoupling pulses are anticipated.6.4. Field inhomogeneity
The typical spectral full width at half maximum (FWHM) of a
given resonance is equal to 1/pT2, and becomes 1/pT2* when the
inﬂuence of ﬁeld inhomogeneity (gDB0) is taken into account, i.e. 1/
T2* ¼ 1/T2þgDB0. The effect of ﬁeld inhomogeneity (gDB0) on the
FWHMs of 13C resonances is reduced four-fold compared to that
observed for 1H resonances due to g13C/g1H ¼ 0.25 [74]. Nonethe-
less, the inﬂuence of ﬁeld inhomogeneity on 13C resonances be-
comes substantial especially when large VOIs in combination of
high magnetic ﬁelds are commonly used for 13C-MRS detection of
glycogen, in beneﬁt of improved sensitivity. Taking the example of a
(8  5  5) mm3 volume, typically used for 13C MRS measurement
of cerebral glycogen in rats, improving ﬁeld homogeneity with
shimming may reduce the linewidth of the water 1H resonance
from 126 Hz to 15 Hz at 9.4 T, i.e. yielding a reduction of 111 Hz
(0.28 ppm), as experimentally measured in our system. A more
pronounced effect of shimming was observed for our 14.1T system:
the linewidth of water 1H resonance was reduced from 580 Hz to
22 Hz, i.e. yielding a reduction of 558 Hz (0.9 ppm). Considering a
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tional to 1FWHM and thus the signal amplitude change can be esti-
mated as II* ¼ FWHM
*
FWHM , in which I* and FWHM* stand for signal
amplitude and linewidth without any shimming compensation,
respectively. Therefore, taking the example at 14.1 T, a reduction of
558 Hz on the linewidth of the water 1H signal translates into a 24-
fold increase of the water signal amplitude. Such ﬁeld in-
homogeneity is expected to induce a 140 Hz widening effect on the
FWHM of 13C MR spectra since g13C/g1H ¼ 0.25 (1/T2* ¼ 1/
T2þg13CDB0). When the FWHM of glycogen 13C-1 is 64 Hz at 14T
(i.e., FWHM ¼ 1/pT2 with T2 ¼ 5 ms, Table 1), the ﬁeld in-
homogeneity may enlarge the FWHM* of glycogen 13C-1 resonance
to ~200 Hz, and consequently induces a >3-fold reduction of its
amplitude.
Overall, shimming minimizes ﬁeld inhomogeneity and thus in-
creases T2*, translating into narrowing linewidth and increasing
signal amplitude. The need of adjusting shim coils becomes
important, especially at ultra-high magnetic ﬁelds.
6.5. Localization
Spatial localization deﬁnes the VOI and is essential for reliable
non-invasive detection of cerebral 13C-glycogen. In particular, non-
echo based localization methods are desired to deﬁne a 3D volume
within the brain tissue, given the ultra-short T2 of glycogen
(Table 1).
6.5.1. Chemical shift imaging (CSI)
Chemical shift imaging (CSI) is one approach to perform local-
ization in MRS [88,89]. For instance, 1D CSI requires an additional
phase-encoding gradient to deﬁne spatial localization and has been
applied for liver glycogen detection by 13C-MRS in humans [89].
Many approaches have been pursued to shorten the acquisition
time for CSI whilst maintaining the desired sensitivity, e.g. using a
sampling k-space scheme [90]. Alternatively, Fourier series window
(FSW) became useful for the development of surface coil rotating
frame experiments, which depend on an inhomogeneous B1 ﬁeld
gradient for excitation [91,92]. However, the dephasing step in the
FSW is not as efﬁcient as single-voxel localization spectroscopy. For
instance, the SNR per time unit in the FSWapproach in detection of
13C glycogen was ~30% less than that of single-voxel 13C-MRS
studies [93]. In addition, the Fourier transform reconstruction can
lead to intervoxel signal contamination from the very nearby
extracerebral glycogen due to point spread function effects.
Therefore, single-voxel localization remains the preferred method
for 13C-MRS detection of glycogen in brain, as discussed in the
following paragraphs.
6.5.2. Image-selected In vivo spectroscopy (ISIS)
This method explores the slice-selective principle of MRI tech-
niques for localizing MR signals from a speciﬁc volume, as sug-
gested by Ordidge and coworkers [94], and has been applied for
13C-MRS detection of liver glycogen in humans [95]. The technique
is based on a slice-selective inversion of spins prior to their exci-
tation and signal acquisition. More speciﬁcally, to obtain an MR
signal from a given slice, two scans are required. In the ﬁrst, the free
induction decay (FID) is obtained with all the spins in the volume
having the same phase; in the second, the FID is acquired in the
same way except that spins in the target slice are ﬁrst inverted
using a slice selective 180 pulse.When the two FIDs are subtracted,
only the signal from the target slice remains. The 3D volume can be
localized using linear combinations of such scheme in three di-
rections and a minimum number of eight scans is necessary for
canceling out unwanted signals from outside the target volume.
One advantage of this method is the absence of T2 weighting,since there is no echo time in this pulse sequence. However, ISIS
relies on inverting spins in the VOI, which can result in signal loss
due to T1 of glycogen and imperfect slice proﬁles. An additional
caveat of the add-subtract scheme of ISIS is that it makes locali-
zation vulnerable to any subtraction errors related to motion or RF
pulse imperfections.
6.5.3. Outer volume suppression (OVS)
Instead of exciting the spins in the VOI, the slice-selective
schemes with 90 nominal pulses can be applied to destroy
magnetization outside the VOI by ﬂipping it into the transverse
plane and dephasing it with spoiler gradients, so that no net
magnetization outside the VOI remains [66]. In brief, to localize one
dimension, two suppression slices must be placed at both sides of
the VOI and a 3D volume may be deﬁned using three pairs of OVS
pulses. The frequencies of the paired slice-selective pulses are
placed in the center of the suppression slices instead of the center
of the target VOI. Once three pairs of suppression slices are properly
positioned and the pulses are applied, a localized MR spectrum can
be acquired by using a simple non-selective excitation RF pulse. The
selected pair or the entire OVS module can be repeated several
times, to ensure a robust suppression of the surrounding
magnetization.
Similar to ISIS, OVS also allows data acquisition immediately
after the non-selective excitation RF pulse, an advantageous feature
for obtaining accurate signals from metabolites with short T2, such
as glycogen (Table 1). In addition, OVS can achieve localization in
one scan and is, therefore, resistant to motion and system
instability.
It is clear that suppression is the key element to ensure locali-
zation andmust be extremely efﬁcient to avoid contamination from
outside of the VOI. The thickness of the different suppression slices
depends on the placing of the VOI within the coverage of the coil,
and is not necessarily the same for every slice. With increasing
subject size and decreasing VOI size, OVS can be very challenging
since strong signals from the outer volume need to be suppressed,
which requires RF pulses with large bandwidths and high
amplitudes.
OVS per se is usually not efﬁcient enough to obtain clean MR
spectra [66] and is, therefore, used in combination with other
localization techniques, as addressed in the following paragraph for
the case of brain glycogen.
6.5.4. Localized 13C-MRS detection of brain glycogen in practice
To achieve high 13C sensitivity with low 1H power deposition,
the linear-13C coil in combination with the quadrature-1H coil
design has been widely used for rodent [80,86,96] and human
studies [21,82,95,97]. As a result, a 3D localization method of 13C
glycogen adapted to that coil design was developed. This method
was initially developed for the rodent brain and is based on a T1-
optimized OVS scheme [80,96]. In order to detect the sensitive
volume of the 13C coil, reduce B1 and signal variations perpendic-
ular to B0 and the 13C coil (“x” axis, horizontal, Fig. 1), and minimize
contamination from skeletal muscle glycogen, a slice-selective
inversion recovery unit is applied. When the inverted magnetiza-
tion of glycogen from the skeletal muscle right beside the VOI ap-
proaches zero (inversion recovery delay time according to T1 of
glycogen 13C-1), six nominal 90 pulses are applied on the slices
parallel to the VOI to minimize the residual z-magnetization
(Fig. 1B). Due to the usage of the 13C-linear surface coil, the per-
formance of the OVS perpendicular to the RF coil and B0 (“y” axis,
vertical, Fig. 1) is compromised. Therefore, an additional 1D ISIS
with corresponding phase cycling is applied in conjunction with a
y-slice gradient containing the VOI (Fig. 1B).
After the OVS-ISIS localization modules, an adiabatic half-
Fig. 1. Improvements of a pulse sequence for 13C-MRS detection of glycogen in the rat brain. A) After a 4 h infusion of 20% w/v [1e13C]glucose, a project proﬁle of glycogen 13C-1
(99e102 ppm) between two dashed lines with 1D CSI approach [89] shows that glycogen signals arise from skeletal muscle. B) A typical 3D localization 13C MRS pulse sequence
diagram for 13C detection of glycogen in the rat brain [80,96]. The localization performance for glycogen 13C-1 is ensured by applying (ii) a slice inversion unit (blue dashed squares
in B and C); (ii) a 3D OVS unit (red dashed square, an inversion time is optimized for nulling z-magnetization from extracerebral glycogen); and (iii) 1D ISIS on y-axis. Glycogen 13C-1
signal is further enhanced by (i) an adiabatic excitation 90 pulse to increase the excitation volume; and (ii) bi-level WALTZ-16 RF pulses on 1H channel during excitation for NOE
and during signal acquisition for decoupling JCH. C) Once a 3D volume (red square) is deﬁned by the localized 13C MRS, glycogen 13C-1 and glucose 13C-1 can be obtained from rat
brain after the administration of [1e13C] glucose.
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acquisition of the FID. In addition, bi-level WALTZ-16 RF pulses [86]
are applied to the proton channel, enhancing the sensitivity of 13C-1
glycogen detection in two ways: (i) via nuclear Overhauser effect
(NOE) that transfers magnetization from protons to glycogen 13C-1
during excitation; and (ii) affording decoupling of JCH-coupling
during the signal acquisition period.
Due to the use of the 13C-linear surface coil, whose size is
actually smaller than that of the entire brain, it is desired that all RF
pulses used for inversion, saturation and excitation are adiabatic
[80,96]. For instance, the advantages of nominal adiabatic 90 hy-
perbolic secant pulses used for OVS [98] are (i) to be tailored to
meet the speciﬁc needs of the in vivo geometry within the RF power
limits, (ii) to provide a B1-insensitive slice selection proﬁle and (iii)
to minimize chemical shift displacement errors through broad
bandwidth of the pulse. In the case of excitation and inversion, the
adiabatic pulse, above a certain B1 threshold, offers the same
nutation independent of B1 amplitude and is beneﬁcial for a large
VOI [96,98].
The overall method initially developed for studies of the rodent
brain was modiﬁed and optimized to be applied to humans. Spe-
ciﬁcally, in the latter case and unlike for the rodent brain, there is no
surrounding skeletal muscle to potentially contaminate the VOI
with extracerebral glycogen. Therefore, no slice-selective recovery
module is included in the 13C-MRS sequences used for human
studies of brain glycogen [21,76].7. Experimental aspects of 13C-MRS of cerebral glycogen
7.1. Quantiﬁcation of cerebral glycogen detected by 13C MRS
To obtain quantitative information from 13C-MR spectra ac-
quired in vivo, glycogen 13C-1 signal is converted to concentration.
Internal reference methods are often the choice for quantiﬁcation
in 1H-MRS, where a standard compoundmeasured in the spectrum
(e.g. creatine) or tissue water are used for scaling. However, these
methods are not applicable to 13C-MRS of cerebral glycogen due to
the absence of a natural abundance 13C signal from any highlyconcentrated compound in the brain. An alternative option is to
reproduce 13C-MRSmeasurements in vivo on a phantom containing
an aqueous glycogen solution of known concentration, the so-
called external reference method [71]. To accurately perform this
method, a reference 13C signal from a13C-enriched compound (e.g.
formic acid in a closed sphere) should be provided at the 13C coil for
corrections related with coil performance, such as loading or ad-
justments of transmitting and receiving powers [71,97]. Other
factors, including T1, T2 and NOE, have to be taken in to account
between the external reference phantom solution and in vivo scans.
In addition, some imperfections can be corrected by the external
reference method, namely off-resonances effects [74]. As
mentioned in the previous section, the intrinsic characteristic of the
applied adiabatic half passage pulses for excitation is to offer the
same nutation ﬂip angles (e.g. 90 is desired for a maximal excita-
tion for detection of glycogen 13C-1) independent of B1 amplitude
when the carrier frequency of the pulse is equal to the Lamar fre-
quency of spins of the target metabolite, so called on-resonance.
This feature is often accompanied by non-uniform RF excitation
proﬁles away from the carrier frequency of the excitation pulse, i.e.
off-resonance [99e101]. Therefore, adjacent metabolites are
affected by a possible sub-maximal excitation, so called off-
resonance effects. For instance, when studies measure both
glucose and glycogen 13C-1 signals with the carrier frequency on
the resonance near glycogen 13C-1 (100.5 ppm), an accurate
quantiﬁcation of both molecules from their 13C signals has to
consider the extent to which such off-resonance effects impact the
nearby glucose 13C-1 signals (96.8 and 93.2 ppm) [102]. The effects
can be reproduced in phantoms of known glycogen and glucose
concentrations, thereby allowing to correct the data acquired
in vivo.7.2. Administration of 13C-enriched glucose
The administration of 13C-labeled precursors (typically [1e13C]
glucose) is essential to enrich the brain glycogen pool with 13C to
levels detectable by 13C-MRS in vivo. This experimental strategy not
only facilitates glycogen quantiﬁcation, as it also allows to follow
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the glucose precursor is continuously delivered to the blood
stream. With this approach, 13C-MRS becomes a very insightful
technique to characterize cerebral glycogen metabolism in animals
and humans in vivo (recently reviewed by Khowaja A et al., 2015
[2]). The rationale behind tracer2 studies of brain glycogen meta-
bolism is explored in the following paragraphs, with examples from
published studies in rats and humans.
There are two approaches to enrich cerebral glycogen with 13C
from 13C-labeled glucose: (i) by continuous infusion of the labeled
precursor [57,58,77,80,96]; or (ii) with extensive pre-labeling by ad-
libitum ingestion [18]. Both methods have been combined to study
brain glycogen kinetics in rats after a 24 h pre-labeling period,
when complete turnover3 of the brain glycogen pool is achieved
[81,93].7.2.1. Isotopic enrichment and glycogen content
In studies using 13C-labeled precursors, isotopic enrichment of
both precursor and product should be characterized for an accurate
and comprehensive interpretation of metabolic ﬂuxes [103]. In the
case of glycogen kinetics, this means assessing the isotopic
enrichment of both glycogen and glucose in the brain.
Upon administration of a13C-glucose tracer, its isotopic enrich-
ment will be diluted by endogenous unlabeled glucose, essentially
from hepatic glucose production. As a result, the isotopic enrich-
ment of brain glucose, available for glycogen synthesis, will be well
below that of the administered tracer. This effect can be minimized
under a continuous glucose infusion by co-infusing insulin, which
limits hepatic production of unlabeled glucose. Given the rapid
equilibration of glucose across the blood brain barrier [57]
[104e106], isotopic enrichment of arterial glucose is essentially
that of brain glucose, what has been conﬁrmed in brain extracts in
rats [81]. Hence, the 13C enrichment of plasma glucose may be used
as a surrogate of that of brain glucose, an assumption relevant for
human studies [21,37,59].
Assessing the isotopic enrichment of glycogen is the only way to
verify whether the pool has been completely turned over and also
to obtain the total concentration of glycogen (both 13C and 12C). In
animal experiments, the isotopic enrichment of brain glycogen can
be determined directly in tissue extracts [58]. In addition, deter-
mination of brain glycogen isotopic enrichment has been afforded
by using N-acetyl-aspartate as a reporter molecule in the rat brain
in vivo [18]. Importantly, this method has been validated in rats
against in vitro measurements in tissue extracts [81]. In humans,
non-invasive assessments of brain glycogen isotopic enrichment
remain to be demonstrated.
The isotopic enrichment of glycogen is dependent on the iso-
topic enrichment of brain glucose and glycogenmetabolic turnover,
as illustrated in Fig. 2. For example after 1e2 days pre-labeling [81],
the isotopic enrichment of glycogen was similar to that of brain
glucose, indicating complete glycogen turnover, but below that of
glucose in the drinking water, due to dilution by endogenous
glucose production. In contrast, when 99% [1e13C]glucose was
continuously infused to maintain moderate hyperglycemia over
several hours [58], the isotopic enrichment of brain glucose (~90%)2 13C-labeled precursors used to follow given metabolic pathways are actually
administered at doses that largely surpass tracer amounts to improve sensitivity of
13C-MRS detection. For instance, isotopic enrichment of [1e13C]glucose used as a
precursor for brain glycogen in 13C-MRS studies in vivo ranges from 25% (in
humans) to 99% (in rats).
3 Refers to the rate at which glucosyl units in glycogen are replaced by new ones,
derived from the administered tracer, via simultaneous synthesis and breakdown.
Complete turnover means that all the glucosyl units have been replaced, which
yields that the glycogen pool exists at isotopic and metabolic steady state.was close to that of the infusate but the isotopic enrichment of
glycogen was signiﬁcantly lower (~77%). Therefore, the latter
ﬁndings denote negligible dilution from endogenous glucose pro-
duction but non-complete glycogen turnover.
7.2.2. Glycogen synthesis, breakdown and turnover by 13C MRS
The brain glycogen pool reﬂects the activity of enzymes with
opposite effects: glycogen synthase (adding glucosyl units to
glycogen) and glycogen phosphorylase (removing glucosyl units
from glycogen). Because the activities of both enzymes occur
simultaneously, increases in glycogen 13C-1 following the infusion
of [1e13C]glucose may denote simple turnover (accumulation of
13C-glycogen without changes in total concentration) and/or net
synthesis (effective increase in total glycogen concentration). The
relative contribution of each of those phenomena will depend on
the experimental and pathophysiological conditions. For example,
with 48 h pre-labeling Choi and Gruetter [18] found total brain
glycogen concentration to be ~3 mmol/g. Comparatively, after 4 h of
[1e13C]glucose infusion (set to maintain glycemia at 13e16 mM),
brain 13C-glycogen alone was substantially higher, amounting to
5 mmol/g [80], and even more so when glucose infusion was pre-
ceded by an hypoglycemic period inducing supercompensation
[29,58]. Taken together, these studies support the notions that net
glycogen synthesis may take place in the brain under certain con-
ditions such as hyperglycemia and supercompensation.
Resolving synthase and phosphorylase ﬂuxes from net synthesis
is possible by 13C-MRS in vivo with appropriate glucose infusion
tracers and protocols. Valuable kinetic information on enzymatic
ﬂuxes is achieved when label incorporation (or disappearance) into
glycogen 13C-1 is followed and glycogen concentration is at steady-
state, i.e. no net synthesis (or degradation) [107]. For example,
when infusing [1e13C]glucose, changes in glycogen 13C-1 signal
report synthase ﬂux, and conversely when switching the infused
solution to unlabeled glucose the decrease of glycogen 13C-1 re-
ﬂects phosphorylase ﬂux. In such pulse-chase experiments,
glycogen turnover rate has been estimated in rats to be
~0.5 mmol g1.h1, with presumably minimal net glycogen syn-
thesis [80,96]. A similar rate of ~0.7 mmol g1.h1 was found when
the contribution of net synthesis was ruled out, by infusing
[1,6e13C2]glucose at an isotopic enrichment matching that of
glycogen achieved with [1e13C]glucose during a pre-labeling
period [93]. Therefore, brain glycogen turnover in rats is very
slow, with a turnover time4 of ~8 h [80,93,96].
On the other hand, achieving an isotopic stead-state where no
changes are observable on glycogen 13C-1 due to a constant isotopic
enrichment over time, is a pre-requisite to investigate the effect of
speciﬁc conditions (such as variations in insulin or glucose levels,
for instance) on brain glycogen mobilization. Isotopic steady-state
of brain glycogen has been accomplished by means of a pre label-
ing period in rats [81,93] or after prolonged infusion of >5 h in rats
[29] and >48 h in humans [77].
When the above mentioned methodological considerations are
acknowledged, very insightful information on cerebral glycogen
kinetics is achieved. Namely, rodent 13C-MRS studies in vivo
showed that glycogen consumption in the brain increases upon
insulin-induced hypoglycemia and that, when normoglycemia is
restored, glycogen synthesis takes place and supercompensation
occurs [29]. Such studies also indicate that, when sufﬁcient glucose
is present, insulin mainly promotes glycogen turnover rather than
net synthesis [81].4 Turnover time is the time required for all the glycogen to be replaced by newly
synthesized molecules at a given rate, and is given by the ratio between the pool
size (in mmol/g) and the metabolic or turnover rate (in mmol.g1.h1) [18].
Fig. 2. Depiction of glycogen labeling from exogenous 13C-labeled glucose and example spectra of brain glucose and glycogen acquired by 13C-MRS in vivo. Once in the body, the
isotopic enrichment of the administered solution (infused or ingested) is diluted by endogenous unlabeled glucose, and the isotopic enrichment of brain glucose will be reduced in
proportion to that contribution. With time, glycogen becomes progressively labeled as the simultaneous activities of glycogen synthase and phosphorylase replace unlabeled
glucosyl units by 13C-labeled ones via the phosphorylated intermediates glucose-1-phosphate (Glc-1-P) and uridine diphosphate glucose (UDPG). Glycogen turnover is complete
when its isotopic enrichment reaches that of the precursor glucose pool at isotopic steady-state. The ﬁgure illustrates incomplete turnover, commonly observed in the ﬁrst few
hours of infusion studies. Changes in brain glucose and glycogen 13C-1 signals can be followed over time by localized 13C-MRS in vivo, as shown in the stacked 13C spectra (adapted
from the study by Lei et al., 2007 [58]).
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glycogen turnover has been modeled with some assumptions,
yielding a synthesis ﬂux of 0.16e0.28 mmol g1.h1, with turnover
times in the range of days [21,37,59]. Hence, brain glycogen meta-
bolism is slower in humans, relative to that of rats. When glycogen
13C-1 data were ﬁtted with a biophysical model accounting for
synthase and phosphorylase activities at the level of the individual
glucose chain [108], glycogen content in the healthy human oc-
cipital lobe was estimated to be ~8 mmol/g [75]. This ﬁnding is in
close agreement with values determined by 13C-MRS in vivo in the
rodent brain.
In a recent 13C-MRS study in vivo, €Oz et al. were able to detect
alterations in brain glycogen metabolism in diabetic patients, who
displayed lower levels of newly synthesized glycogen relative to
healthy volunteers, a ﬁnding that may indicate reduced brain
glycogen levels and/or slower turnover in diabetic patients [59].
8. Concluding remarks
To date, 13C-MRS remains the state-of-the-art technique to
assess cerebral glycogen and its metabolism in vivo. Despite the
challenges in technical development and biological interpretations,this method has provided valuable insights into brain glycogen
content and kinetics. So far, the potential of MRS to characterize
brain glycogen metabolism in disease has been addressed in type-1
diabetic patients, with limited but promising results. Therefore,
fully elucidating cerebral glycogen metabolism in vivo in patho-
logical conditions remains to be explored and can strongly beneﬁt
from rodent studies that allow for direct validation.
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